Managed Care
Disease
Management

Bivalirudin, Cangrelor, and Stent Thombosis: New Trials Raise More Questions

C. Michael Gibson, MS, MD, of Harvard Medical School, discusses important aspects of the HORIZONS-AMI and EUROMAX trials and tackles the question of whether a longer infusion of bivalirudin could lead to a reduced risk of stent thrombosis within 24 hours.